	US 12,441,790 B2
	Binding proteins to the human thrombin receptor, PAR4
Justin Hamilton, Clayton (AU); and Mark Sleeman, Clayton (AU)
Assigned to MONASH UNIVERSITY, Clayton (AU)
Filed by MONASH UNIVERSITY, Clayton (AU)
Filed on Aug. 30, 2023, as Appl. No. 18/240,347.
Application 18/240,347 is a continuation of application No. 16/646,554, granted, now 11,780,915, previously published as PCT/AU2018/050985, filed on Sep. 11, 2018.
Claims priority of application No. 2017903685 (AU), filed on Sep. 11, 2017.
Prior Publication US 2024/0117031 A1, Apr. 11, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 7/02 (2006.01)

CPC C07K 16/28 (2013.01) [A61K 47/6849 (2017.08); A61P 7/02 (2018.01); C07K 2317/34 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

15 Claims

1. A protease activated receptor 4 (PAR4) binding protein which is an anti-PAR4 recombinant or synthetic or monoclonal antibody or antigen-binding fragment thereof, wherein the protein specifically binds to an epitope which spans the thrombin cleavage site of PAR4 and comprises:

a VH having a CDR1, CDR2 and CDR3 sequence comprising SEQ ID NO:59, SEQ ID NO:60 and SEQ ID NO:61, and a VL having a CDR1, CDR2 and CDR3 sequence comprising SEQ ID NO:57, GAS and SEQ ID NO:62.